Longevity Health’s $99M Merger with 20/20 BioLabs Ignites Healthy Aging Revolution

April 14, 2025

DENVER, Colo., Apr 14, 2025 (247marketnews.com)- Longevity Health (NASDAQ:XAGE) sealed a merger agreement with 20/20 BioLabs, in an all-stock deal that may redefine healthy aging. Hot on the heels of Longevity’s Elevai Skincare deal, this fusion propels XAGE into an estimated $100 billion healthy aging market, with a $99 million post-merger valuation.

20/20 BioLabs, a CLIA-licensed, CAP-accredited lab in Gaithersburg, MD, brings firepower: its OneTest, a $200 blood test detecting cancers like lung and pancreatic early, outshone rivals in a 2024 NCI study. Integrated into checkups for thousands of firefighters and veterans, it uses pain-free capillary samples, a market first. A Giant Food pilot launches this week, and a Spring 2025 longevity test targeting inflammation-driven aging is set to drop. With 10 quarters of sales growth, 20/20 is a diagnostics beast.

Jonathan Cohen, 20/20’s CEO, said, “We are excited by the market, product and operational synergies between 20/20 and Longevity. We believe 20/20 is a leader in offering access to lab testing in non-traditional settings, such as homes and retail locations. We expect this Merger will expand our reach to MedSpas and other channels covered by Longevity’s existing customer base.”

The combo doubles XAGE’s 2025 revenue from $3-4 million to $7-8 million, slashing $1 million in costs and blends Longevity’s Elevai bio-aesthetics with 20/20’s tests for tailored protocols.

Valued at $50 million pre-merger, 20/20 grabs 50.1% of the Nasdaq-listed XAGE, with Longevity at 49.9%, with earnouts that could tip it further.

Rajiv Shukla, Longevity’s CEO, who will remain Chairman, with a six-director board split evenly, added, “We are happy to announce a merger with 20/20 in line with our previously announced corporate rebranding and acquisition strategy. This merger is expected to double our fiscal year 2025 revenue forecast and put us on the path to profitability. Additionally, there are exciting product and market synergies between our product portfolios. We anticipate announcing further acquisitions in fiscal year 2025 that we believe will be value accretive to our stockholders.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (XAGE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.